Gene therapy of lymphoma

Journal of Hematotherapy and Stem Cell Research

Volumn 11, Issue 3, 2002, Pages 457-467

  Buttgereit, Peter ^a   Schmidt Wolf, Ingo G H ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; CELL TYPE; DNA TRANSFER; DNA VECTOR; GENE EXPRESSION; GENE INSERTION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HOST CELL; IMMUNE RESPONSE; LYMPHOCYTE; LYMPHOMA; MAMMAL CELL; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW; TRANSGENE; TUMOR CELL;

ANIMALS; GENE THERAPY; HUMANS; IMMUNOTHERAPY; LYMPHOMA; TRANSDUCTION, GENETIC;

EID: 0036276959     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/15258160260090924     Document Type: Review

References (91)

1. Gene therapy: Lessons learnt from the past decade. Interview by Clare Thompson
2. Wild-type p53 induces apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53
3. In vitro adenoviral vector p53-mediated transduction and killing correlates with expression of coxsackie-adenovirus receptor and alpha(nu)beta5 integrin in SUDHL-1 cells derived from anaplastic large-cell lymphoma
4. Adenovirus-p53-mediated gene therapy of anaplastic large cell lymphoma with t(2;5) in a nude mouse model
5. Transfer of marker genes into hemopoietic progenitor cells
6. Gene marking
7. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
8. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model
9. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice
10. BCL2 antisense therapy in patients with non-Hodgkin lymphoma
11. Phase 1 clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
12. Control of c-myc regulation in normal and neoplastic cells
13. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth
14. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model
15. Prevention of tumor formation in a mouse model of Burkitt's lymphoma by 6 weeks of treatment with antic-myc DNA phosphorothioate
16. Inhibition of tumorigenesis in a murine B-cell lymphoma transplant model by c-Myc complementary oligonucleotides
17. Preclinical antisense DNA therapy of cancer in mice
18. Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) sensitizes EBV-immortalized B cells to transforming growth factor-beta and chemotherapeutic agents
19. The p53 tumour suppressor gene
20. p53-dependent apoptosis suppresses tumor growth and progression in vivo
21. p53, the cellular gatekeeper for growth and division
22. The 1993 Walter Hubert Lecture: The role of the p53 tumour-suppressor gene in tumorigenesis
23. p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia
24. p53 is frequently mutated in Burkitt's lymphoma cell lines
25. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus
26. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer
27. Genetic mechanisms of tumor suppression by the human p53 gene
28. Effects of adenoviral wild-type p53 gene transfer in p53-mutated lymphoma cells
29. Adenoviral vectors efficiently target cell lines derived from selected lymphocytic malignancies, including anaplastic large cell lymphoma and Hodgkin's disease
30. Efficient gene transfer into lymphoma cells using adenoviral vectors combined with lipofection
31. Efficient adenovirus-mediated gene expression in malignant human plasma cells: Relative lymphoid cell resistance
32. In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug
33. Adenovirus vector infection of chronic lymphocytic leukemia B cells
34. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach
35. Absence of in vitro or in vivo bystander effects in a thymidine kinase-transduced murine T lymphoma
36. Efficient gene delivery into epsteinbarr (EBV)-transformed human B cells mediated by replication-defective herpes simplex virus-1 (HSV-1): A gene therapy model for EBV-related B cell malignancy
37. Cytokines and gene therapy
38. Cytokines and clinical gene therapy
39. Generation of dendritic cell-based vaccines for cancer therapy
40. Gene therapy of hematologic malignancies
41. Irradiated IL-2 gene-modified plasmacytoma vaccines are more efficient than live vaccines
42. + killer cells
43. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity
44. Phase I clinical study applying autologous immunologic effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma
45. T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154
46. Immunogenetic therapy for B-cell malignancies
47. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia
48. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
49. ONYX-015: Clinical data are encouraging
50. Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells
51. Rapid transgene expression in lymphocyte and macrophage primary cultures after particle bombardment-mediated gene transfer
52. Improving stable transfection efficiency: Antioxidants dramatically improve the out-growth of clones under dominant marker selection
53. On the mechanism of DNA transfection: Efficient gene transfer without viruses
54. Increase of proliferation rate and enhancement of antitumor cytotoxicity of human CD3+CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene
55. A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1
56. Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2
57. Lymphocyte apoptosis: Induction by gene transfer techniques
58. P53 tumor suppressor gene therapy for cancer
59. Gene therapy using adenovirus vectors
60. Upregulation of integrins alpha v beta 3 and alpha v beta 5 on human monocytes and T lymphocytes facilitates adenovirus-mediated gene delivery
61. Interaction of human adenovirus serotype 2 with human lymphoid cells
62. Efficient adenovirus-mediated gene transduction of normal and leukemic hematopoietic cells
63. Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: Evidence for reduced toxicity and enhanced antitumor activity in mice
64. Mechanism of adenovirus improvement of cationic liposome-mediated gene transfer
65. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5
66. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment
67. The levels of integrin alpha v beta 5 may predict the susceptibility to adenovirus-mediated gene transfer in human lung cancer cells
68. Increased transduction efficiency of primary hematopoietic cells by physical colocalization of retrovirus and target cells
69. + cells maintains regeneration capacity and enhances adhesion molecules in K562 cells
70. Adenoviral-mediated gene transfer in lymphocytes
71. High-efficiency transfer of the T cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors
72. A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells
73. Suitability of Epstein-Barr virus-based episomal vectors for expression of cytokine genes in human lymphoma cells
74. Suppression of the tumorigenic growth of Burkitt's lymphoma cells in immunodeficient mice by cytokine gene transfer using EBV-derived episomal expression vectors
75. Targeted, non-viral gene delivery for cancer gene therapy
76. Targeting of adenoviral vectors through a bispecific singlechain antibody
77. Targeted adenovirus-mediated gene delivery to T cells via CD3
78. Efficient transduction of murine B lymphocytes and B lymphoma lines by modified adenoviral vectors: Enhancement via targeting to FcR and heparan-containing proteins
79. Adenovirus vector pseudotyping in fiber-expressing cell lines: Improved transduction of Epstein-Barr virus-transformed B cells
80. + cells via electroporation-mediated gene delivery
81. Retroviral transduction of T lymphocytes for suicide gene therapy in allogeneic stem cell transplantation
82. + T lymphocytes
83. Gene therapy for B cell lymphomas
84. Gene and cell transfer for specific immunotherapy
85. Gene therapy: Trials and tribulations
86. Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome
87. Targeting of natural killer-like T immunologic effector cells against leukemia and lymphoma cells by reverse antibody-dependent cellular cytotoxicity
88. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an EIB-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial